HC Wainwright Cuts Earnings Estimates for Evaxion A/S

Evaxion A/S – Sponsored ADR (NASDAQ:EVAX) – Stock analysts at HC Wainwright dropped their FY2027 EPS estimates for shares of Evaxion A/S in a note issued to investors on Monday, March 9th. HC Wainwright analyst S. Ramakanth now expects that the company will post earnings of $5.50 per share for the year, down from their previous estimate of $7.00. HC Wainwright currently has a “Buy” rating and a $16.00 price target on the stock. The consensus estimate for Evaxion A/S’s current full-year earnings is ($0.15) per share. HC Wainwright also issued estimates for Evaxion A/S’s FY2028 earnings at $2.00 EPS, FY2029 earnings at $4.00 EPS and FY2030 earnings at ($0.50) EPS.

Evaxion A/S (NASDAQ:EVAX) last announced its quarterly earnings results on Thursday, March 5th. The company reported $0.30 earnings per share (EPS) for the quarter.

Several other equities research analysts also recently commented on the company. Lake Street Capital dropped their target price on Evaxion A/S from $11.00 to $9.00 and set a “buy” rating on the stock in a report on Monday. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Evaxion A/S in a research report on Friday, January 9th. Maxim Group started coverage on shares of Evaxion A/S in a research note on Thursday, February 19th. They set a “buy” rating and a $10.00 price objective on the stock. Finally, JonesTrading started coverage on shares of Evaxion A/S in a research report on Tuesday. They set a “buy” rating and a $10.00 target price on the stock. Five research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, Evaxion A/S has a consensus rating of “Moderate Buy” and a consensus target price of $11.00.

Evaxion A/S Price Performance

Shares of NASDAQ EVAX opened at $3.87 on Wednesday. The company has a debt-to-equity ratio of 0.41, a current ratio of 5.85 and a quick ratio of 5.85. Evaxion A/S has a 1-year low of $1.20 and a 1-year high of $12.15. The company has a market capitalization of $32.28 million, a price-to-earnings ratio of -2.93 and a beta of 0.28. The business has a 50-day moving average of $3.83 and a 200-day moving average of $4.62.

Institutional Trading of Evaxion A/S

A number of hedge funds have recently made changes to their positions in the stock. SmartHarvest Portfolios LLC bought a new stake in shares of Evaxion A/S in the fourth quarter worth $72,000. Wesbanco Bank Inc. bought a new position in Evaxion A/S during the 4th quarter valued at $48,000. Finally, Northwestern Mutual Wealth Management Co. acquired a new position in Evaxion A/S during the 4th quarter worth $38,000. Institutional investors and hedge funds own 11.04% of the company’s stock.

Evaxion A/S News Summary

Here are the key news stories impacting Evaxion A/S this week:

• Positive Sentiment: Jones Trading initiated coverage with a Buy rating and a $10 price target — a new institutional endorsement that increases visible demand and analyst support. Jones Trading initiates coverage of Evaxion A (EVAX) with buy recommendation
• Positive Sentiment: HC Wainwright reaffirmed its Buy rating and a $16 price target — a high target relative to the current price that supports upside expectations from a well‑known biotech analyst. HC Wainwright Reaffirms Buy Rating for Evaxion A/S (NASDAQ:EVAX)
• Positive Sentiment: Q4 2025 earnings call highlighted strategic partnerships and financial resilience — language that reassures investors on near‑term funding and execution risk. Evaxion AS (EVAX) Q4 2025 Earnings Call Highlights: Strategic Partnerships and Financial Resilience
• Positive Sentiment: Short interest fell ~36% in February (now ~1.1% of float), reducing downward pressure from short sellers and potentially supporting a short‑squeeze dynamic on positive news. No external link
• Negative Sentiment: Lake Street Capital cut its price target to $9, lowering one analyst anchor on valuation and moderating near‑term upside expectations. Lake Street Capital Lowers Evaxion A/S (NASDAQ:EVAX) Price Target to $9.00
• Negative Sentiment: HC Wainwright trimmed several longer‑range EPS forecasts (FY2027–FY2030 updates show lower EPS vs prior estimates), which reduces modeled long‑term earnings and implies the stock’s upside depends on execution and pipeline milestones. (HC Wainwright still maintains a Buy and $16 PT.) No external link

About Evaxion A/S

Evaxion A/S is a clinical-stage biotechnology company headquartered in Copenhagen, Denmark, with additional operations in the United States. The company specializes in the development of immunotherapies and vaccines driven by its proprietary AI-based computational immunology platform. By leveraging machine learning and deep learning algorithms, Evaxion identifies and optimizes antigen targets for both therapeutic cancer vaccines and prophylactic vaccines against infectious diseases.

At the core of Evaxion’s business is its AI platform, which analyzes large datasets of genomic, proteomic and immunological information to predict immune-stimulating epitopes.